Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.

Casper RokxJaime F Borjas HowardColette SmitFerdinand W WitElise D PietermanPeter Reiss Suzanne C CannegieterWillem M LijferingKarina Meijer Wouter F W Bierman Vladimir Y I G TichelaarBart J A Rijndersnull null

Published in: PLoS medicine (2020)

Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE.

Keyphrases

venous thromboembolism
direct oral anticoagulants
antiretroviral therapy
stem cells
bone marrow
cell therapy